Radioimmunoimaging and radioimmunotherapy: Will these be routine procedures?

Seminars in Nuclear Medicine

Volumn 30, Issue 3, 2000, Pages 186-194

  Delaloye, Angelika Bischof ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARCITUMOMAB TC 99M; FLUORODEOXYGLUCOSE F 18; GALLIUM; MONOCLONAL ANTIBODY;

ANTIBODY LABELING; BONE SCINTISCANNING; CANCER STAGING; DOSIMETRY; DRUG DISTRIBUTION; DRUG UPTAKE; GENETIC ENGINEERING; IMMUNOSCINTIGRAPHY; MALIGNANT NEOPLASTIC DISEASE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; REVIEW;

EID: 0033941609     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2000.7440     Document Type: Article

References (79)

1. Bischof Delaloye A Delaloye B Tumor imaging with monoclonal antibodies Semin Nucl Med 25 1995 144 164
2. Bischof Delaloye A Delaloye B Radiolabelled monoclonal antibodies in tumour imaging and therapy: Out of fashion? Eur J Med 22 1995 571 580
3. (suppl) Jain RK Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors Cancer Res 50 1990 814 819
4. Hertel A Baum RP Auerbach B Klinische Relevanz humaner Anti-Maus Antikörper (HAMA) in der Immunszintigraphie Nuklearmedizin 29 1990 221 227
5. Moffat FL Jr Pinsky CM Hammershaimb L Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial. The Immunomedics Study Group J Clin Oncol 14 1996 2295 2305
6. Hardman N Lee Gill L Winter de RFJ Generation of a recombinant human-mouse chimaeric monoclonal antibody directed against human carcinoembryonic antigen Int J Cancer 44 1989 424 433
7. Buchegger F Mach JP Pelegrin A Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma J Nucl Med 36 1995 420 429
8. Griffiths AD Williams SC Hartley O Isolation of high affinity human antibodies directly from large synthetic repertories EMBO J 13 1994 3245 3260
9. Morrison SL Success in specification Nature 368 1994 812 813
10. Holliger P Winter G Diabodies: Small bispecific antibody fragments Cancer Immunol Immunother 45 1997 128 130
11. Kipriyanov SM Moldenhauer G Schuhmacher J Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics J Mol Biol 293 1997 41 56
12. Terskikh AV Le Doussal JM Crameri R “Peptabody”: A new type of high avidity binding protein Proc Natl Acad Sci U S A 94 1997 1663 1668
13. Goodwin DA Meares CF McCall MJ Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens J Nucl Med 29 1988 225 234
14. Le Doussal JM Martin M Gautherot E In vitro and in vivo targeting or radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate J Nucl Med 30 1989 1358 1366
15. Kalofonos HP Ruschowski M Siebecker DA Imaging of tumor in patient with In-111-labeled biotin and streptavidin-conjugated antibodies: Preliminary communication J Nucl Med 31 1990 1791 1796
16. Paganelli G Belloni C Magnani P Two-step tumour targeting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin Eur J Nucl Med 19 1992 322 329
17. Breitz HB Weiden PL Beaumier PL Clinical optimization of pretargeted radioimmunotherapy with antibodystreptavidin conjugate and 90Y-DOTA biotin J Nucl Med 41 2000 131 140
18. Oyen WJG van Horn JR Claessens AMJ Diagnosis of bone, joint, and joint prothesis infections with indium-111-labeled nonspecific human immunoglobulin G Radiology 182 1992 195 199
19. Seybold K Locher JT Coosemans C Immunoscintigraphic localization of inflammatory lesions: Clinical experience Eur J Nucl Med 13 1988 587 593
20. Lind P Langsteger W Költringer P Immunoscintigraphy of inflammatory processes with a technetium-99m-labeled monoclonal antigranulocyte antibody (MabBW 250/183) J Nucl Med 31 1990 417 423
21. Hotze AL Briele B Overbeck B Technetium-99m-labeled anti-granulocyte antibodies in suspected bone infections J Nucl Med 33 1992 526 531
22. Boubaker A Bischof Delaloye A Blanc CH Immunoscintigraphy with antigranulocyte monoclonal antibodies for the diagnosis of septic loosening of hip prostheses Eur J Nucl Med 22 1995 139 147
23. Reske SN Karstens JH Gloeckner W Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma Lancet 1 1989 299 301
24. Altehoefer C Blum U Bathmann J Comparative diagnostic accuracy of magnetic resonance imaging and immunoscintigraphy for detection of bone marrow involvement in patients with malignant lymphoma J Clin Oncol 15 1997 1754 1760
25. Bischof Delaloye A Delaloye B Buchegger F Clinical value of immunoscintigraphy in colorectal carcinoma patients: A prospective study J Nucl Med 30 1989 1646 1656
26. Rigo P Positron emission tomography using 18F-fluorodeoxyglucose in oncology Bull Mem Acad R Med Belg 152 1997 353 361
27. Schiepers C Hoh CK Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer Ann Surg 227 1998 324 325
28. Ferrand SK Chen CC Dilsizian V What is new in nuclear medicine imaging? Surg Oncol Clin N Am 8 1999 185 204
29. Weber WA Avril N Schwaiger M Relevance of positron emission tomography (PET) in oncology Strahlenther Onkol 175 1999 356 373
30. Flanagan FL Dehdashti F Ogunbiyi OA Utility of FDG-PET for investing unexplained plasma CEA elevation in patients with colorectal cancer Ann Surg 227 1998 319 323
31. McGuirt WF Greven K Williams D III PET scanning in head and neck oncology review Head Neck 20 1998 208 215
32. Hoh CK Seltzer MA Franklin J Positron emission tomography in urological oncology (Review) J Urol 159 1998 347 356
33. Silverman DH Hoh CK Seltzer MA Evaluating tumor biology and oncological disease with positron-emission tomography (Review) Semin Rad Oncol 8 1998 183 196
34. Sugawara Y Braun DK Kison PV Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: Preliminary results Eur J Nucl Med 25 1998 1238 1243
35. Sugawara Y Gutowski TD Fisher SJ Uptake of positron emission tomography tracers in experimental bacterial infections: A comparative biodistribution study of radiolabeled FDG, thymidine, L-methionine, 67Ga-citrate, and 1251-HSA Eur J Nucl Med 26 1999 333 341
36. Guhlmann A Brecht-Krauss D Suger G Fluorine 18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis Eur J Nucl Med 39 1998 2145 2152
37. (abstr) Stumpe KDM Dazzi H Schaffner A PET imaging of inflammatory lesions J Nucl Med 25 1999 908
38. Britton K Highlights of the Annual Meeting of The European Association of Nuclear Medicine, Lausanne, 1993 Eur J Nucl Med 21 1994 159 169
39. Philpott GW Schwarz SW Anderson CJ RadioimmunoPET detection of colorectal carcinoma with positronemitting copper-64-labeled monoclonal antibody J Nucl Med 36 1995 18 24
40. Goldenberg DM Perspectives on oncologic imaging with radiolabeled antibodies Cancer 80 suppl 1997 2431 2435
41. Adams S Baum RP Hertel Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen Nucl Med Commun 19 1998 641 647
42. Pasquali C Rubello D Sperti C S. Neuroendocrine tumor imaging: Can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22 1998 588 592
43. Shreve PD Grossman HB Gross MD Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose Radiology 199 1996 751 756
44. Hofer C Laubenbacher C Block T Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy Eur Urol 36 1999 31 35
45. Seltzer MA Barbaric Z Belldegrun A Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer J Urol 162 1999 1322 1328
46. Haseman MK Reed NL Rosenthal SA Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation Clin Nucl Med 21 1996 704 713
47. Kalkner KM Nilsson S Bergstrom M PET with hydroxytryptophan as tracer in hormone-refractory prostatic adenocarcinoma: Evaluation of decarboxylation in vivo In Vivo 11 1997 377 381
48. Hara T Kosaka N Kishi H PET imaging of prostate cancer using carbon-11-choline J Nucl Med 39 1998 990 995
49. (abstr) Delaloye B Bischof Delaloye A Pettavel J Intra-arterial administration of 131-I-anti-CEA-Mab as a therapeutic approach to liver metastases Nucl Med 26 1987 52
50. Meredith RF Khazaeli MB Liu T Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer J Nucl Med 33 1992 1648 1653
51. (suppl) Murray JL Macey DJ Kasi LP Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer Cancer 73 1994 1057 1066
52. Breitz HB Weiden PL Vanderheyden JL Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trial J Nucl Med 33 1992 1099 1112
53. Sharkey RM Weadock KS Natale A Successful radioimmunotherapy for lung metastases of human colonic cancer in nude mice J Natl Cancer Inst 83 1991 627 632
54. Behr TM Memtsoudis S Vougioukas V Radioimmunotherapy of colorectal cancer small volume disease and in an adjuvant setting: Preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial Anticancer Res 19 1999 2427 2432
55. Crippa F Bolis G Seregni E Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer Eur J Cancer 31A 1995 686 690
56. Nicholson S Gooden CS Hird V Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis Oncol Rep 5 1998 233 236
57. suppl Riva P Franceschi G Frattarelli M Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: A phase I study Clin Cancer Res 5 1999 3275S 3280S
58. Paganelli G Grana C Chinol M Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin Eur J Nucl Med 26 1999 348 357
59. (suppl) Kraeber-Bodere F Bardet S Hoefnagel CA Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial Clin Cancer Res 5 1999 3190S 3198S
60. O'Donoghue JA Implications of nonuniform tumor doses for radioimmunotherapy J Nucl Med 40 1999 1337 1341
61. (suppl) DeNardo SJ DeNardo GL O'Grady LF Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies Int J Cancer 3 1998 96 101
62. Kaminski MS Zasadny KR Francis IR Radioimmunotherapy of B-cell lymphoma with (131I) anti-B1 (anti-CD20) antibody N Engl J Med 329 1993 459 465
63. Press OW Eary JF Appelbaum FR Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support New Engl J Med 329 1993 1219 1224
64. Press OW Eary JF Appelbaum FR Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas Lancet 346 1995 336 340
65. Kaminski MS Zasadny KR Francis IR Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma J Clin Oncol 14 1996 1974 1981
66. Liu SY Eary JF Petersdorf SH Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue J Clin Oncol 16 1998 3270 3278
67. (suppl) Behr TM Wormann B Gramatzki M Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies Clin Cancer Res 5 1999 3304S 3314S
68. Gates VL Carey JE Siegel Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy J Nucl Med 39 1998 1230 1236
69. (suppl) DeNardo GL DeNardo SJ O'Grady LF Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1 Cancer Res 50 1990 1014S 1016S
70. Witzig TE White CA Wiseman GA Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+)B-cell non-Hodgkin's lymphoma J Clin Oncol 17 1999 3793 3803
71. DeNardo SJ DeNardo GL Kukis DL Cu-67-21T-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma J Nucl Med 40 1999 302 310
72. Bischof Delaloye A Delaloye B Buchegger F Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors J Nucl Med 38 1997 847 853
73. Waibel R Alberto R Willuda AR Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex Nat Biotechnol 17 1999 897 901
74. Seitz U Neumaier B Glatting G Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia Eur J Nucl Med 26 1999 1265 1273
75. Nikula TK McDevitt MR Finn RD Alphaemitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry J Nucl Med 40 1999 166 176
76. McLendon RE Archer GE Larsen RH Radiotoxicity of systemically administered At-211-labeled human/mouse chimeric monoclonal antibody: A long-term survival study with histologic analysis Int J Radiat Oncol Biol Phys 45 1999 491 499
77. Jurcic JG Scheinberg DA Radionuclides as conditioning before stem cell transplantation. (Review) Curr Opin Hematol 6 1999 371 376
78. (suppl) Couturier O Faivre-Chauvet A Filippovich IV Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma Clin Cancer Res 5 1999 3165S 3170S
79. Johnson TA Press OW Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas Int J Cancer 85 2000 104 112